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a b s  t r a  c t
Recent studies have shown that some drugs that are not routinely used to treat fungal
infections have antifungal activity, such as protease inhibitor antiretroviral drugs. This study
investigated the  in vitro susceptibility of Histoplasma capsulatum var. capsulatum to saquinavir
and  ritonavir, and its  combination with the antifungal itraconazole. The susceptibility assay
was performed according to Clinical and Laboratory Standards Institute guidelines. All
strains  were inhibited by  the protease inhibitor antiretroviral drugs. Saquinavir showed min-
imum  inhibitory concentrations ranging from 0.125 to 1 g mL−1 for both phases, and riton-
avir presented minimum inhibitory concentrations ranging from 0.0312 to 4 g mL−1and
from 0.0625 to 1 g mL−1 for filamentous and yeast phase, respectively. Concerning the anti-
fungal itraconazole, the minimum inhibitory concentration values ranged from 0.0019 to
0.125 g  mL−1 and from 0.0039 to 0.0312 g mL−1 for the filamentous and yeast phase, respec-
tively.  The combination of saquinavir or ritonavir with itraconazole was synergistic against
H.  capsulatum,  with a significant reduction in the minimum inhibitory concentrations of both
drugs against the strains (p < 0.05). These data show an  important in vitro synergy between
protease inhibitors and itraconazole against the fungus H.  capsulatum.
© 2016 Published by Elsevier Editora Ltda. This is an  open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Histoplasmosis is a systemic infection caused by the dimor-
phic fungus Histoplasma capsulatum. It is mainly associated
with immunosuppression, especially in  HIV patients.1,2 This
disease is characterized by a  broad spectrum of clinical
manifestations ranging from asymptomatic to  dissemi-
nated forms.3 Histoplasmosisis is  widely distributed in the
Americas.4 In Brazil, the number of cases has increased in
several regions. Some outbreaks have been recorded in the
country, involving the states of Rio de Janeiro, São Paulo, Minas
Gerais, Espírito Santo, Mato Grosso, and Rio Grande do Sul.4–6
In Ceará state, a  recent study reported 254 cases of histoplas-
mosis in patients with HIV in the period from 2006 to 2010,
showing its high prevalence in  this region.7
Treatment of histoplasmosis depends on the severity of
infection, clinical manifestations and individual risk factors.
The therapy indicated for mild to moderate cases is the
administration of azoles, such as  itraconazole. The use of
amphotericin B is limited to severe cases because of its high
toxicity. Due to the increase of histoplasmosis cases in recent
years, particularly among HIV patients, associated with the
occurrence of refractory and recurrent infections, there is
a need to find new therapeutic approaches to control this
mycosis.8,9 Some studies have shown that certain drugs not
routinely used to treat fungal infections have significant anti-
fungal activity.10 Among these, the antiretroviral drugs have
demonstrated the ability to interfere with the viability and vir-
ulence of fungal cells. The protease inhibitors indinavir and
ritonavir have shown in vitro and in vivo inhibitory effects
against Candida albicans.11 Indinavir also has shown activity
against the fungus Cryptococcus neoformans,  reducing its viru-
lence and making it more  susceptible to the killing activity of
natural effector cells of the immune system.12
Thus, this study aimed to  evaluate the in vitro susceptibil-
ity of H. capsulatum var. capsulatum to the antiretroviral drugs
saquinavir and ritonavir, as well as  their combination with the
azole antifungal itraconazole.
Materials  and  methods
Microorganisms
We  used a total of 20 clinical strains of H. capsulatum in  the fil-
amentous phase and 10 in  the  yeast phase, isolated from the
Northeast and Southeast regions of Brazil. The samples came
from the culture collection of the Specialized Medical Mycol-
ogy Center, Federal University of Ceará, and were handled in
a biosafety level 3  cabin.
Antifungal  agents
Stock solutions of the  antiretroviral drugs saquinavir (Roche
Holding AG, Basel, Switzerland) and ritonavir (Abbott Labora-
tories, Chicago, USA) and the  antifungal itraconazole (Janssen
Pharmaceutica, Beerse, Belgium) were prepared in dimethyl
sulfoxide (DMSO). These solutions were stored at −20 ◦C
until use. Serial dilutions of each antimicrobial agent were
prepared in RPMI 1640 (Sigma Chemical Corporation, St. Louis,
MO, USA), supplemented with l-glutamine, buffered at a  pH
of 7.0 with MOPS 165 mmol  l−1 (Sigma Chemical Corporation,
St. Louis, MO, USA).
Preparation  of  fungal  inoculum
To prepare the inoculum, fungal suspensions were prepared
in saline from stock cultures after seven days of incubation,
maintained on BHI (brain heart infusion) agar and incubated
at 28 ◦C for the filamentous phase. The cultures were main-
tained on BHI agar supplemented with sheep blood at 10%  and
incubated at 35 ◦C to obtain the yeast phase. The inoculum
was adjusted to 90–95% by transmittance spectrophotometry
at a wavelength of 530 nm. After reading, the suspensions
were diluted 1:10 in  RPMI 1640 medium to  obtain inoculums
of approximately 0.5 × 103 to 2.5 × 104 cfu mL−1.13
Susceptibility  test
The in vitro antifungal activity was determined by the
broth microdilution method in accordance with the  pro-
tocol described in  document M27-A3 and standardized by
the Clinical Laboratory Standards Institute.14 Initially, the
minimum inhibitory concentration (MIC) was  determined
for each drug. Subsequently, the MIC values were used
as the highest concentration to prepare drugs in com-
bination. The concentration ranges of the drugs alone
were: 0.0039–2 g mL−1 for saquinavir, 0.0156–8 g  mL−1 for
ritonavir, and 0.0009–0.5 g  mL−1 for itraconazole. The con-
centration ranges of the drugs in combination were:
0.0002–1 g mL−1 for saquinavir, 0.00006–4 g mL−1 for riton-
avir and 0.000003–0.0625 g mL−1 for itraconazole. The results
were determined by visual readings after seven and four
days of incubation at 35 ◦C for strains in the filamentous and
yeast phase, respectively. The MICs were defined as the low-
est  concentration of drug able to  inhibit 80% of the fungal
growth for antiretroviral drugs and itraconazole, as well as
for the combination of both.13 Drug interaction was evaluated
by calculating the  fractional inhibitory concentration index
(FICI), which was classified as  synergistic (FICI ≤ 0.5), indiffer-
ent (0.5 < FICI < 4), or antagonistic (FICI ≥ 4).15 The FICI values
obtained for each drug combination against H. capsulatum
were compared through Wilcoxon test (p < 0.05). The analy-
sis was carried out using IBM SPSS ver. 21.0 software (IBM
Co., Armonk, NY, USA). Standard strains of Candida parapsilo-
sis ATCC 22019 and Candida krusei ATCC 6258 were included in
each test as  quality controls.
Results
The protease inhibitors saquinavir and ritonavir were capa-
ble of inhibiting the strains of H. capsulatum,  with MIC values
ranging from 0.125 to 1 g  mL−1 for saquinavir in both fila-
mentous and yeast phase; and from 0.0312 to 4 g  mL−1 and
from 0.0625 to 1 g mL−1 for ritonavir in  filamentous and yeast
phase, respectively (Table 1). Concerning itraconazole, the
MIC ranged from 0.0019 to 0.0625 g mL−1 and from 0.0039 to
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Table 1 – MICs of antiretroviral drugs and itraconazole against strains of Histoplasma capsulatum var. capsulatum in
yeast-like and mycelial forms.
Strains Saquinavi (g  mL−1) Ritonavir (g mL−1)  Itraconazole (g mL−1)
Mycelial form
0.125  (2)a 0.0312 (1)  0.0019 (2)
0.25 (6) 0.125 (1)  0.0078 (4)
0.5 (8) 0.5 (4)  0.0156 (6)
1 (4) 1 (5)  0.0312 (6)
2 (5)  0.0625 (2)
4 (4)
Yeast form
0.125  (3) 0.0625 (4)  0.0039 (1)
0.25 (1) 0.125  (3) 0.0078  (4)
0.5 (4) 0.5  (2) 0.0156  (2)
1 (2) 1  (1) 0.0312  (3)
a Number of tested strains.
0.0312 g mL−1 for the filamentous and yeast phase, respec-
tively (Table 1).
Synergistic interactions were observed for the combi-
nations of saquinavir or ritonavir with itraconazole, and
there was a  significant reduction in  the MIC of these drugs:
saquinavir (p  = 0.0000) and itraconazole (p = 0.0000) for fila-
mentous and yeast phases; and ritonavir (p  = 0.0001) and
itraconazole (p = 0.0003) for filamentous phase and riton-
avir (p = 0.0297) and itraconazole (p = 0.0015) for yeast phase
(Table 2). No antagonistic interactions were observed.
Discussion
In recent years, studies have shown that HIV patients can have
substantially longer life expectancy, depending on adherence
to antiretroviral treatment and the evolution of the immune
status. Also, the use of more  effective therapy decreases the
incidence of opportunistic infections, including histoplasmo-
sis. Even though the use of protease inhibitors, including
saquinavir, has been associated with the development of
several side effects, recent studies have demonstrated that
the use of  liposome saquinavir formulations significantly
decreases the levels of cytotoxicity, besides improving the
bioavailability of this drug.16
Moreover, it has been observed that the protease inhibitors
can have beneficial effects on some fungal infections, not only
by modulating the immune system of the susceptible host,
but also by exerting direct action against the pathogen.17 It
has also been observed from in vitro and in  vivo studies that
protease inhibitors reduce the pathogenicity and growth of C.
albicans probably because these drugs act directly on the pro-
duction of the enzyme aspartyl-proteinases, which is secreted
by this organism in the  processes of invasion and colonization
of host tissues.18–20 Additionally, it has been shown that riton-
avir inhibits the in vitro hyphal growth rate of C. albicans,21
ritonavir and saquinavir inhibit the adherence of C. albicans
to endothelial cells,22 and saquinavir, ritonavir, and indinavir
attenuate the  in vitro adherence of C. albicans to acrylic sub-
stances, which is  a  common component of oral appliances.23
More recently, it was observed that the protease inhibitors
saquinavir, darunavir, ritonavir, and indinavir did not reduce
the in  vitro growth of C. neoformans, but reduced protease activ-
ity as  well as capsule production, important virulence factors
of C. neoformans.24 Although there are some studies on the
action of protease inhibitors against fungi, no reports for H.
capsulatum have been published so far.
In the present study, we observed that the protease
inhibitors saquinavir and ritonavir alone inhibited H. capsu-
latum, and saquinavir and ritonavir interacted synergistically
with itraconazole, as evidenced by the increased in vitro activ-
ity of the antifungal drug. The advantage of the  synergistic
effect of the combination of antiretroviral and antifungal
drugs aims to attenuate toxic effects caused by them, espe-
cially in  cases of long-term therapies, such as in HIV-infected
patients presenting with histoplasmosis.2
Casolari et  al.25 found that saquinavir alone did  not show
significant antifungal activity against the yeast forms of C.
Table 2 – Effects of the combination of antiretroviral drugs and itraconazole on strains of H. capsulatum var. capsulatum in
yeast-like and mycelial forms.






Results Number of strains
presenting synergism
Antiretroviral Antifungal Antiretroviral Antifungal
Mycelial
form
SAQ/ITC 0.4 0.01 0.002 0.0001 0.007 S 20/20
RIT/ITC 1.03 0.01 0.27 0.004 0.5 S 13/20
Yeast
form
SAQ/ITC 0.45 0.01 0.02 0.001 0.12 S 10/10
RIT/ITC 0.15 0.01 0.01 0.001 0.16 S 10/10
SAQ = saquinavir; RIT  = ritonavir; ITC = itraconazole; S = synergistic interaction.
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albicans and C. neoformans. However, when combined with the
azole drug fluconazole, it was found to inhibit the growth of
these fungal species, indicating the occurrence of synergism
between the drugs. Similarly, Palmeira et  al.26 described the
effect of nelfinavir and saquinavir against the dematious fun-
gus Fonsecaea pedrosoi and confirmed that these compounds
alone were unable to inhibit the growth of this fungus.
However, inhibition did  occur when sub-inhibitory doses of
these protease inhibitors were combined with amphotericin
B. Mikus et al.27 noted that ritonavir prolongs the clearance of
voriconazole, although the use of ritonavir with voriconazole
is contraindicated because the  former lowers the plasma
levels of voriconazole.
Our data demonstrated an in vitro synergistic interaction
between saquinavir or ritonavir with itraconazole against the
dimorphic fungus H. capsulatum. The mechanism underlying
the observed synergy remains unknown, but Crommentuyn
et al.28 showed that the in vivo combination of antiretroviral
lopinavir/ritonavir and itraconazole interacts through phar-
macokinetic pathways, interfering with the metabolism of the
antifungal drug, which increases the  plasma level of the anti-
fungal agent, thus, making it possible to reduce the dosage of
itraconazole without impairing the  treatment. Based on our
findings, we  believe that saquinavir or ritonavir with itracona-
zole interact probably through pharmacodynamic pathways.
These data show an important in  vitro synergy between
saquinavir or ritonavir and itraconazole against the fungus H.
capsulatum,  which is an  important pathogen for AIDS patients.
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